GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Meda Pharmaceuticals Inc. and Cipla Ltd. today announced that they sued Apotex Inc. and Apotex Corp. (“Apotex”) in Federal District Court in Delaware to enforce the Orange-Book listed patents covering Dymista (azelastine HCl/fluticasone propionate) Nasal Spray in response to Apotex’s submission to the US Food and Drug Administration (“FDA”) of an Abbreviated New Drug Application (“ANDA”), and accompanying Paragraph IV certification, seeking approval to market a generic version of Meda’s Dymista prior to expiration of the Dymista patents.
Help employers find you! Check out all the jobs and post your resume.
